irreversible and progressive brain disorder that causes problems with memory,
thinking, orientation and behavior. The symptoms arise due to development
of plaques and tangles
that causes the loss of connections between nerve cells
(neurons) in the brain and their death.
‘A new biochip-based blood test helps to run multiple tests on one blood sample to detect people at increased risk of Alzheimer’s disease.’
There are two types of Alzheimer's, early-onset
and late-onset. Most people with Alzheimer's have the
late-onset form of the disease, in which symptoms appear after the age of 60 years. Late-onset Alzheimer's
can be attributed to a combination of
genetic, environmental, and lifestyle factors. People survive for 8-10 years after the onset of the disease.
Death usually results from pneumonia, general body wasting or malnutrition.
disease is caused by gene mutations
in one of three genes: APP, PSEN1, or PSEN2 that can be passed from parents to children. The late-onset Alzheimer's
disease can be attributed to a form of the apolipoprotein E
(ApoE4) gene on
chromosome 19 that increases the person's risk for Alzheimer's disease. However, not every person with APOE E4 allele will develop the
disease and sometimes those who have the disease may not have the allele. Testing of the gene currently helps scientists to look for early
brain changes in those positive for the allele and compare the effectiveness of
treatments for people with different APOE profiles.
new biochip test detects the presence of a
protein in the blood produced by the ApoE4 variation. When patient person
inherits the ApoE4 variant from one parent, he/she has a three times greater
risk of developing Alzheimer's disease, whereas a person who inherits the ApoE4
variant from both parents is eight-to-12 times more likely to develop the
verify the accuracy of the biochip test, researchers from Randox Laboratories
collaborated with research colleagues at the Medical University of Vienna. They
analyzed 384 samples and compared the results of the biochip test with a
standard DNA test.. They found that the two tests were similar in detecting the
risk for Alzheimer's disease. The biochip test allows clinicians and
researchers to run multiple tests on one sample of blood.. It gives results in
three hours and is more affordable than the standard DNA test.
is the first time that we have used this biochip technology to test for an
increased risk of Alzheimer's disease," said Emma C. Harte, PhD, a research
scientist at Randox Laboratories. "This type of testing is important in our
quest to understand and diagnose Alzheimer's and empower patients to understand
risks, consider medication, and even make early lifestyle changes."
this test with medical and family history for risk of Alzheimer's disease has
the real potential to advance personalized medicine," said Harte. "This fast,
accurate testing will allow doctors and patients to make more informed choices
earlier to potentially slow the possible progress of Alzheimer's."
Currently, ApoE4 testing is mainly used in
research settings to identify study participants who may have an increased risk
of developing Alzheimer's disease. However, since the test cannot accurately
predict that the person will develop Alzheimer's disease, its use in the general
population is currently not advised. Researchers also believe that ApoE gene testing is useful for
studying the risk of Alzheimer's disease in large groups of people but not at an individual level.
- Alzheimer's Disease Genetics Fact Sheet -
testing - (https://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=434)
Is Alzheimer's? - (http://www.alz.org/alzheimers_disease_what_is_alzheimers.asp)
disease - (https://ghr.nlm.nih.gov/condition/alzheimer-disease#genes)